Archives

by in
Entry Author Date Location
Exclusive: OVP Venture Partners, NW’s Oldest VC Firm, To Shut Down 10/11/12 Seattle
Betting on Biotech to Catalyze U.S. Job Growth? Don’t Count On It 10/01/12 National
Seattle Genetics Gets $34.7M in Second-Quarter Sales of Cancer Drug 08/08/12 Seattle
U.S. Biotech Clusters Are Losing Their Anchor Tenants, and It Hurts 08/06/12 National
Actinium Advances Armed Cancer Drugs, Preps for Wall Street Debut 08/01/12 New York
Seattle Genetics, Millennium Get EU Recommendation for Lymphoma Drug 07/20/12 Seattle
Life Science Innovation NW Notes: SeaGen, NanoString, Viket, & More 07/12/12 Seattle
Gates Foundation’s Jeff Raikes To Start Off Seattle Biotech Event 07/10/12 Seattle
The Best Boring Companies in Biotech 07/09/12 National
Merck Bets $15M on Ambrx’s “Smart Bomb” Antibodies 06/18/12 San Diego
ASCO Wrap-Up: A Summary of This Week’s Cancer R&D Headlines 06/05/12 National
NanoString Nabs Ex-Seattle Genetics Exec to Lead Diagnostic Push 05/29/12 Seattle
Seattle Genetics Follows the Science, Taking on Rare Lymphoma No. 3 05/23/12 Seattle
Who’s on Biotech’s Endangered Species List? Mid-Sized Drugmakers 05/21/12 National
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies 05/16/12 National
Seattle Genetics Misses 1st Quarter Sales Estimate, But Sees $1B Future 05/08/12 Seattle
Sutro Biopharma Pulls in $16M for New Antibody Drugs 05/08/12 San Francisco
Mersana Adds $4M For Next-Generation “Armed” Cancer Drugs 05/01/12 Boston
Abbott’s Humira, the 3rd-in-Class Drug That Toppled Lipitor as No. 1 04/16/12 National
Seattle Genetics Digs Deeper Into the Proverbial Haystack 03/13/12 National
Reinventing Biotech on April 3: Here’s the Agenda 03/08/12 Seattle
Seattle Genetics Gets New Commercial Boss for Early Days of Adcetris 02/23/12 Seattle
Seattle Genetics Sees Updated Side Effect Warning in Drug Label 01/13/12 Seattle
Xconomy Seattle’s Top 12 Life Sciences Stories of the Year 12/28/11 Seattle
The Year in Seattle Biotech: Lots of Acquisitions, Few New Startups 12/22/11 Seattle
Seattle Genetics, Millennium Look to Broaden Reach of Hodgkin’s Drug 12/09/11 Seattle
Scale Venture Partners Gives Up On Healthcare & Life Sciences Investing 11/08/11 San Francisco
Groupon: The IPO With More Sizzle, and Money, Than the Entire Biotech IPO Class of 2011 11/07/11 National
Seattle Genetics Beats Expectations With $10M Sales in Lymphoma Drug Debut 11/03/11 Seattle
Analyst: Seattle Genetics on Pace to Smash Wall Street Forecast with Lymphoma Drug Rollout 10/20/11 Seattle
Page 2 of 9 « previous page · next page »